90947-07-2

Usage

Uses

Used in Pharmaceutical Research and Development:
1-oxo-1,2-dihydroisoquinoline-5-carbonitrile is used as a building block for the synthesis of various bioactive compounds, contributing to the development of new pharmaceuticals.
Used in Production of Pharmaceuticals and Agrochemicals:
1-oxo-1,2-dihydroisoquinoline-5-carbonitrile serves as a versatile intermediate in the manufacturing process of pharmaceuticals and agrochemicals, enhancing their efficacy and applications.
Used in Medicinal Chemistry for Antimicrobial and Antifungal Applications:
1-oxo-1,2-dihydroisoquinoline-5-carbonitrile is studied for its potential biological activities, particularly its antimicrobial and antifungal properties, making it a valuable compound in the field of medicinal chemistry for the development of treatments against infections.

Upstream product

• 212374-17-9 2-((E)-2-Dimethylamino-vinyl)-isophthalonitrile 
• 2317-22-8 2,6-dicyanotoluene 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 212374-18-0 1-oxoisoquinoline-5-carboxylic acid 
• 1192829-90-5 ethyl 4-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]butanoate 
• 1192829-61-0 3-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]benzoic acid 
• 1192829-60-9 4-[5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1-isoquinolinyl]butanoic acid 
• 1192829-88-1 5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1(2H)-isoquinolinone 
• 1192829-89-2 1-bromo-5-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)isoquinoline 

Relevant academic research and scientific papers

Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)

Inhibitors of poly(ADP-ribose)polymerase (PARP) inhibit repair of damaged DNA and thus potentiate radiotherapy and chemotherapy of cancer. 3-Substituted benzamides and 5-substituted isoquinolin-1-ones have been synthesised and evaluated for inhibition of PARP. Reduction of 3-(bromoacetyl)benzamide, followed by treatment with base, gave RS-3-oxiranylbenzamide. Reduction of 3-(hydroxyacetyl)benzonitrile with bakers' yeast gave the R-diol which was converted to R-3-(1,2-dihydroxyethyl)benzamide. Similar reduction of 3-(acetoxyacetyl)benzonitrile led towards the S-diol which was converted to its cyclic acetonide. E-2-(2,6-Dicyanophenyl)-N,N-dimethylethenamine was formed by condensation of 2,6-dicyanotoluene with dimethylformamide dimethyl acetal (DMFDMA); cyclisation under acidic conditions afforded 5-cyanoisoquinolin-1-one. Heck coupling of 5-iodoisoquinolin-1-one with propenoic acid formed E-3-(1-oxoisoquinolin-5-yl)propenoic acid. 3-Oxiranylbenzamide, 5-bromoisoquinolin-1-one and 5-iodoisoquinolin-1-one were among the most potent inhibitors of PARP activity in a preliminary screen in vitro. Copyright (C) 1998 Elsevier Science Ltd.